ANI Pharmaceuticals (ANIP) Stock Statistics & Valuation Metrics

ANI Pharmaceuticals has a market cap or net worth of $1.35B. The enterprise value is $892.43M.

ANI Pharmaceuticals has 21,651,072 shares outstanding. The number of shares has decreased by -2.65% in one year.

ANI Pharmaceuticals’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 0.04%.

The current PE Ratio of ANI Pharmaceuticals is -57.66. ANI Pharmaceuticals’s PEG ratio is -0.17.

In the last 12 months, ANI Pharmaceuticals had revenue of 614.38M and earned -18.52M in profits. Earnings per share was -0.87.

In the last 12 months, operating cash flow was 80.74M and capital expenditures -12.37M, giving a free cash flow of 68.37M billion.

ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

ANI Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.

ANI Pharmaceuticals as a current ratio of 2.72, with Debt / Equity ratio of 80.11%

In the past 12 months, ANI Pharmaceuticals has paid -3.69M in taxes.

ANI Pharmaceuticals EV to EBITDA ratio is 19.55, with an EV/FCF ratio of 32.87.

ANI Pharmaceuticals has $149.80M in cash and marketable securities with $317.53M in debt, giving a net cash position of $167.73M billion.

Gross margin is 53.45%, with operating margin of 0.10%, and net profit margin of -3.01%.

The average price target for ANI Pharmaceuticals is $85.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy